EX-16.1 2 v335838_ex16-1.htm EXHIBIT 16.1

 

February 21, 2013

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, N. E.

Washington, D.C. 20549

Ladies and Gentlemen:

We have read the comments made regarding us in Item 4.01 (a) of Form 8-K/A of Bioanalytical Systems, Inc. dated February 21, 2013 and are in agreement with those statements.

Crowe Horwath LLP

Fort Wayne, Indiana

cc: Mr. Larry Boulet

Audit Committee Chairman

Bioanalytical Systems, Inc.